Endothelial dysfunction as a complication of anti-cancer therapy
JD Terwoord, AM Beyer, DD Gutterman - Pharmacology & therapeutics, 2022 - Elsevier
Recent strides in anti-cancer therapeutics have improved longevity and led to a growing
population of cancer survivors, who are increasingly likely to die of other causes. Treatment …
population of cancer survivors, who are increasingly likely to die of other causes. Treatment …
Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress
JC Bikomeye, JD Terwoord… - American Journal of …, 2022 - journals.physiology.org
Many anticancer therapies (CTx) have cardiotoxic side effects that limit their therapeutic
potential and cause long-term cardiovascular complications in cancer survivors. This has …
potential and cause long-term cardiovascular complications in cancer survivors. This has …
Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies
S Sun, J Qin, W Liao, X Gao, Z Shang, D Luo… - Cardiovascular …, 2023 - Springer
The advent of BCR-ABL tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the
treatment of chronic myeloid leukemia (CML) patients. Mitochondria are the key organelles …
treatment of chronic myeloid leukemia (CML) patients. Mitochondria are the key organelles …
Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors
RJ Travers, A Stepanian, IZ Jaffe - … , Thrombosis, and Vascular …, 2024 - ahajournals.org
Kinase inhibitors (KIs) targeting oncogenic molecular pathways have revolutionized cancer
therapy. By directly targeting specific tumor-driving kinases, targeted therapies have fewer …
therapy. By directly targeting specific tumor-driving kinases, targeted therapies have fewer …
[HTML][HTML] Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia
M Takaba, T Iwaki, T Arakawa, T Ono… - Journal of …, 2022 - Elsevier
Although the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia
is known to cause vascular adverse events (VAEs), the frequency of VAEs during dasatinib …
is known to cause vascular adverse events (VAEs), the frequency of VAEs during dasatinib …
[HTML][HTML] Loss of field of view due to optical mismatch at the inner diametric plane of cylindrical artificial microvessels
AG Koutsiaris - Results in Optics, 2022 - Elsevier
In the experimental research with cylindrical artificial microvessels it may not be possible to
view the entire inner diameter, due to optical mismatch between the microvessel material …
view the entire inner diameter, due to optical mismatch between the microvessel material …
Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors
M Nakamae, H Nakamae, M Hashimoto, H Koh… - International Journal of …, 2022 - Springer
Abstract Treatment of chronic myelogenous leukemia (CML) requires management of long-
term use of tyrosine kinase inhibitors (TKIs). Although cardiovascular adverse events (CAEs) …
term use of tyrosine kinase inhibitors (TKIs). Although cardiovascular adverse events (CAEs) …
[PDF][PDF] Results in Optics
AG Koutsiaris - researchgate.net
In the experimental research with cylindrical artificial microvessels it may not be possible to
view the entire inner diameter, due to optical mismatch between the microvessel material …
view the entire inner diameter, due to optical mismatch between the microvessel material …